3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Carcinoma, Medullary
9
Lung Neoplasms
8
Thyroid Neoplasms
7
Neoplasms
5
Neoplasm Metastasis
5
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Stomach Neoplasms
2
Pleural Effusion
2
Kidney Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Familial medullary thyroid carcinoma
2
Fallopian Tube Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid cancer, medullary
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Small Cell Lung Carcinoma
1
Recurrence
1
Rectal Neoplasms
1
Precancerous Conditions
1
Peritoneal Neoplasms
1
Oligodendroglioma
1
Multiple Endocrine Neoplasia Type 2b
1
Multiple Endocrine Neoplasia Type 2a
1
Interventions
Gemcitabine
31
Cisplatin
21
pembrolizumab
8
Fluorouracil
6
Oxaliplatin
5
Capecitabine
5
130-nm albumin-bound paclitaxel
5
durvalumab
4
Taxes
4
Albumin-Bound Paclitaxel
4
pemigatinib
3
infigratinib
3
atezolizumab
3
Specimen Handling
3
Radiosurgery
3
Platinum
3
Magnetic Resonance Spectroscopy
3
Leucovorin
3
Carboplatin
3
Biopsy
3
1,2-diaminocyclohexaneplatinum II citrate
3
tremelimumab
2
trametinib
2
olaparib
2
ivosidenib
2
derazantinib
2
cobimetinib
2
Trastuzumab
2
Radiotherapy
2
Panitumumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Cholangiocarcinoma
×
vandetanib
×
Clear all
NCT00753675
2016-10-10
VANGOGH
Sanofi
Phase 2
Completed
174 enrolled
12 charts